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1 Abstract
2 Purpose: To investigate the placebo effect of caffeine on pacing strategy and performance 
3 over 1000-m running time-trials using a balanced placebo design. Methods: Eleven well-
4 trained male middle-distance athletes performed seven 1000-m time-trials (one 
5 familiarisation, two baseline and four experimental). Experimental trials consisted of the 
6 administration of four treatments: informed caffeine/received caffeine (CC), informed 
7 caffeine/received placebo (CP), informed placebo/received caffeine (PC), and informed 
8 placebo/received placebo (PP). Treatments were randomized. Split times were recorded at 
9 200-, 400-, 600-, 800- and 1000-m and peak heart rate (HRpeak) and rating of perceived 
10 exertion (RPE) were recorded at the completion of the trial. Results: Relative to baseline, 
11 participants ran faster during CC (d = 0.42) and CP (d = 0.43). These changes were 
12 associated with an increased pace during the first half of the trial. No differences were shown 
13 in pacing or performance between baseline and the PC (d = 0.21) and open administration of 
14 placebo (d = 0.10). No differences were reported between treatments for HRpeak (η2 = 0.084) 
15 and RPE (η2 = 0.009). Conclusions: Our results indicate that the effect of believing to have 
16 ingested caffeine improved performance to the same magnitude as actually receiving 
17 caffeine. These improvements were associated with an increase in pace during the first half of 
18 the time-trial.
19 Key words: belief, deception, ergogenic aids, nutrition, sport supplements
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20 Introduction
21 The placebo effect is a desirable outcome resulting from a person’s belief and/or learned 
22 response to a treatment or situation.1 Although there is considerable evidence for the effect 
23 placebos can have on sports performance,2 empirical evidence within sport and exercise 
24 science has remained largely static in regards to the degree to which placebo effects interact 
25 with the verum components of a treatment. Attempts to quantify the placebo effect in sport 
26 and exercise science often rely exclusively on randomized control trials in which participants’ 
27 belief about the treatment they have been administered is held constant by blinding. Using 
28 this type of design nevertheless does not provide sufficient information about whether there 
29 are any interactions between a treatment and the belief that the treatment will influence 
30 performance.3 Authors in placebo effect research4,5 have therefore advocated the use of the 
31 four-treatment, balanced placebo design,6 which allows an assessment of each possible 
32 combination of what the participant believes they have taken and what they have actually 
33 taken.
34 To our knowledge, seven studies have used the balanced-placebo design to examine the 
35 placebo effect on sport performance.4,5,7-11 While most studies using this design have reported 
36 significant placebo effects on time-trial performance,5,7,9 few studies have investigated the 
37 potential mechanisms related to its response. Since the mid-1990s, there has been an 
38 exponential increase in the number of studies investigating the placebo effect and the 
39 neurobiological pathways underlying this phenomenon.2 Qualitative data suggest that placebo 
40 effects may be associated with a reduction in pain sensation, arousal regulation and increases 
41 in motivation,12 which may be mediated and moderated by various neurobiological pathways, 
42 such as the endogenous opioid and neurotransmitter pathways.13 However, while there is 
43 mounting evidence of the mechanisms underpinning this phenomenon, it is unclear how 
44 placebo effects affect sport performance during the actual measure itself. It reasonable to 
45 suggest that after ingesting caffeine, for example, athletes may anticipate an offset in fatigue 
46 and alter their exercise behaviour. Thus, athletes’ pacing strategy may depend on their belief 
47 regarding the effect of a substance and their subsequent decisions during performance.
48 Pacing strategies are set according to an athlete’s expectation of the task they are required to 
49 perform, based on previous experiences that were used to form a performance template.14 
50 Numerous studies have manipulated pacing strategies through deception about timing, the 
51 presence of a competitor and inaccurate feedback. 15 Konings and colleagues16 reported that 
52 when riding against a virtual opponent, time to complete 4-km cycling times trials improved 
53 compared to no opponent due to a faster pace at the start of the time-trial. It has been 
54 suggested that this change in pacing behaviour is influenced through neurotransmitters, such 
55 as dopamine, which are affected by motivation, drive and perception of effort.17 Based on 
56 this, if an athlete receives a treatment they believe to be performance enhancing, that athlete 
57 may be more likely to change their pacing strategy, thereby impacting on performance. 
58 However, to the authors’ knowledge, no study has investigated the effects of a placebo 
59 treatment on pacing strategy. 
60 In this study, we used a balanced placebo design to examine the placebo effects of caffeine 
61 on pacing strategy and performance over 1000-m running time-trials. By using a balanced 
62 placebo design, we specifically aimed to: 1) determine the influence both placebo and 
63 caffeine have on performance and 2) analyse participants’ pacing strategies after 
64 administration of deceptive and open treatments of caffeine and placebo. We also aimed to 
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65 establish whether any changes in performance were associated with changes in peak heart 
66 rate and whether this was made possible by participants’ propensity to knowingly exert more 
67 effort. 
68 Method 
69 Participants and statistical power
70 Eight participants were estimated to provide an a priori statistical power of 0.80. This 
71 estimation was based on a study design using repeated measures ANOVA, an a-value of 0.05 
72 and an explained effect of 1.4 ± 1.6%.18 In case of drop out, fifteen participants were initially 
73 recruited. Four withdrew (two due to injury and two because of a conflicting timetable), 
74 leaving eleven well-trained male middle-distance athletes (mean ± SD: age = 25.2 ± 5.6 yrs; 
75 height = 176.3 ± 8.1 cm; body mass = 66.8 ± 6.1 kg; daily caffeine consumption; 269 ± 43 
76 mg·d-1). Eligibility criteria stipulated that participants must be nationally ranked in the United 
77 Kingdom for 800-, 1500-, 3000- or 5000-m, aged between 18 and 35 and have trained 
78 minimally five days per week for at least 3 months prior to the start of the study. Only light-
79 moderate caffeine (200-350 mg·day-1) users were included in the study to control for 
80 individual differences and familiarity of the effects of caffeine.19 The study was anticipated to 
81 last approximately four weeks. For this reason, only males were recruited to avoid 
82 confounding performance variation in the mid-luteal phase of the menstrual cycle.20 
83 Institutional ethics approval was granted, in agreement with the Declaration of Helsinki. 
84 Participants were informed that participation was voluntary and they had the right to 
85 withdraw at any time during the course of the study. Participants provided written informed 
86 consent after reading the study information sheet.
87 Design
88 We used a quasi-randomised, repeated measures, balanced placebo design to determine the 
89 effects of caffeine and placebo on 1000-m running time-trial performance. Participants 
90 performed seven trials: familiarisation, two baseline and four as part of the balanced placebo 
91 design. The four balanced placebo design trials were as follows:
92 1. Informed caffeine and given caffeine (CC) – participants were informed they received 
93 caffeine and did
94 2. Informed caffeine and given placebo (CP) – participants were informed they received 
95 caffeine but received placebo
96 3. Informed placebo and given caffeine (PC) – participants were informed they received 
97 placebo but received caffeine
98 4. Informed placebo and given placebo (PP) – participants were informed they received 
99 placebo and did
100 The balanced-placebo 1000-m trials were randomised using a computer generated 
101 programme (www.randomization.com) and participants were deceived about the treatment 
102 they received in CP and PC. Particiapts ran 1000-m and split times were recorded at 200-, 
103 400-, 600-, 800- and 1000-m. Peak heart rate (HRpeak) and ratings of perceived exertion 
104 (RPE) were recorded immediately after the trial. 
105 Performance measure and equipment
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106 All trials were run on a 400-m, tartan track, in accordance with the International Association 
107 of Athletics Federation’s standards (polymer synthetic tartan track, with a depth of three 
108 centimetres). Participants ran two and a half laps (1000-m) around the track as fast as 
109 possible, with no assistance (e.g. pacemakers or external feedback). Times and splits were 
110 measured using an automated, single-beam photocell, light gate system (Smartspeed ProTM, 
111 Fusion Sport Inc., Australia) and were mounted in lane 1 of the 200- and 400-m start/finish 
112 line. Single-beam light gate systems are the most common method for measuring running 
113 performance and have shown to have good reliability.21 Weather measurements for wind 
114 speed (m/s), temperature (°C), relative humidity (%) and wind chill (°C) were recorded using 
115 the Pasco weather sensor (PS-2174, Pasco, Roseville CA, USA) attached to the Xplorer GLX 
116 graphing data-logger (PS-2002, Pasco, Roseville CA, USA). Minimal differences were 
117 reported for all time-trials (wind speed = 0.5 ± 0.2m/s; temperature = 18.5 ± 1.9°C; relative 
118 humidity = 53.5 ± 0.9%).
119 Caffeine and placebo treatments
120 Based on previous research in the deceptive administration of caffeine,4 in the CC and CP 
121 treatments, participants ingested 200-mL of chilled saline with 3.0 mg·kg-1 of anhydrous 
122 caffeine (Myprotein; Norwich, England). The dosage of 3.0 mg·kg-1 caffeine was chosen as it 
123 has been suggested to be optimal for improving performance lasting ~3-minutes.22 Given that 
124 peak plasma caffeine typically occurs 45-minutes post-ingestion,23 participants were asked to 
125 consume the treatments 1-hour prior to the start of the time-trial. In the CP and PP treatments, 
126 participants consumed 200-mL of chilled saline only. In placebo effect research, the validity 
127 of the balanced-placebo design relies on the credibility of the deception in the CP and PC 
128 treatments. Extensive pilot testing was therefore conducted to ensure that no taste or 
129 palpability differences could be identified between placebo and caffeine treatments. 
130 Belief manipulation
131 Before any data collection, participants attended a short presentation on the benefits of 
132 caffeine on middle-distance running performance delivered by the first author. Participants 
133 were provided with literature reviewing the findings of published research on caffeine and 
134 middle-distance running and were informed that caffeine was previously a banned 
135 performance enhancing substance. To further augment the belief that caffeine is performance 
136 enhancing, and in line with current recommendations for reporting fine details of participant 
137 contact and communication,2 anecdotal evidence relating to the first authors’ experience in 
138 the use of caffeine was explained. At the time of data collection, the first author competed as 
139 an international level athlete against notable Olympians and participants were informed that 
140 caffeine acted as potent ergogenic aid during competition. The efficacy of this manipulation 
141 of beliefs was supported by data collected in post-study interviews.  
142 Procedure
143 Participants performed seven 1000-m running time-trials. All trials were performed on 
144 Monday and Friday evening at the same location. The time between trials allowed an 
145 adequate wash out period for caffeine supplementation24 and is sufficient for middle-distance 
146 trained athletes to fully recover.25 
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147 For all trials, participants were instructed to arrive in 'race-shape' condition. High intensity 
148 exercise 48 hours preceding the trials was not permitted, as well as the consumption of 
149 alcohol or sport supplements. Participants were asked to adhere to their regular pre-race diet, 
150 rest and warm-up routines. Participants began all trials at the same time of day to minimise 
151 circadian variation in performance26 and each trial was started by a green LED, which would 
152 flash up on the photocell. To limit the potential for participants to employ pacing strategies 
153 based on knowledge of previous trials and performance during trials, they did not to wear a 
154 watch and were given no encouragement. No information about split times was given and the 
155 results of the trials were given after all data had been collected. HRpeak was recorded using a 
156 Polar stopwatch (Heart Monitors, Polar Ltd, Finland) and RPE from 0 (nothing at all) to 10 
157 (maximal) was measured using the Borg Category Ratio27 immediately after participants 
158 completed the trial.   
159 For familiarisation trials, participants were informed: “Today you are performing a 
160 familiarisation trial” and for baseline trials 1 and 2, participants were informed “Today you 
161 are performing a baseline trial”. For balanced placebo design trials, participants were further 
162 reminded about which treatment they had received. For CC and CP treatments, participants 
163 were informed: “Today you will be performing the trial with caffeine” and for PC and PP 
164 treatments, participants were told: “Today you will be performing the trial with no caffeine.” 
165 Upon completion of all data collection, participants were debriefed about the true nature of 
166 the study. 
167 Data analysis
168 Times to complete the 1000-m time-trials for baseline 1 and baseline 2 and each split (200-, 
169 400-, 600-, 800- and 1000-m) were inputted into an online reliability spreadsheet.28 Data 
170 were log transformed to reduce nonuniform errors and the intraclass correlation (ICC) and 
171 Pearson correlation (r) provided estimates of reliability. The precision of ICC was interpreted 
172 as extremely high (0.99); very high (0.90), high (0.75) moderate (0.50) and low (0.20).28 r 
173 was interpreted as trivial (<0.1), small (0.3), moderate (0.5), large (0.5), very large (0.7), 
174 nearly perfect (0.9) and perfect (1.0). In addition, paired samples t-tests were conducted to 
175 determine any systematic difference in performance between baseline 1 and baseline 2. 
176 Data were entered into SPSS version 24.0 (IBM, Armonk, NY) and tested for homogeneity of 
177 variance, normal distribution and anomalies. Repeated measures ANOVA identified 
178 differences in time to complete 1000-m time-trials between each treatment (i.e. baseline, CC, 
179 CP, PC and PP) and split (i.e. 200-, 400-, 600-, 800- and 1000-m). Differences in HRpeak, 
180 RPE and mean time to complete the 1000-m trials between each treatment were also 
181 established using repeated measures ANOVA. Greenhouse-Geisser epsilon was reported 
182 when sphericity was violated and post-hoc LSD tests were used. Cohen’s d was calculated to 
183 determine the effect size (d) of the mean differences. Differences between 0.2 and <0.5 were 
184 interpreted as a small effect, between 0.5 and <0.8 as moderate, and >0.8 as large.29 Data are 
185 presented as mean ± standard error of the mean with statistical significance set at p<0.05 
186 Results
187 Times were similar between baseline 1 and baseline 2 at 200- (mean differences = -0.48 ± 
188 0.34 s, P = .290, r = 0.897, ICC = 0.90), 400- (0.04 ± 0.40 s, p = 0.936, r = 0.776, ICC = 
189 0.77), 600- (-0.56 ± 0.30 s, p = 0.217, r = 0.885, ICC = 0.85), 800- (-0.13 ± 0.53 s, p = 0.149, 
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190 r = 0.584, ICC = 0.61) and 1000-m (0.60 ± 0.61 s, p = 0.189, r = 0.614, ICC = 0.67). The 
191 average of these two time-trials was thus used to measure baseline. Mean times to complete 
192 1000-m trials in all treatments are shown in table 1. 
193
194 Main analyses
195
196 Repeated measures ANOVA (treatment × split) reported differences between treatment (F(4, 
197 160) = 6.162, p = 0.006; η2 = 0.381) and split (F(4, 160) = 9.288, p < 0.001; η2= 0.482). No 
198 difference in time was shown for treatment × split (F(4, 160) = 1.055, p = 0.266; η2= 0.108).
199 Differences in time between treatments
200 Compared to baseline, participants ran faster in CC (mean differences = 0.64 ± 0.11 s, p 
201 <0.001, d = 0.42) and CP (0.66 ± 0.18 s, p = 0.004, d = 0.43) treatments. Compared to PP, 
202 participants ran faster in CC (0.80 ± 0.18 s, p = 0.001, d = 0.47) and CP (0.83 ± 0.21 s, p = 
203 0.002, d = 0.48) treatments. All differences between mean times to complete the trials and 
204 treatments are shown in figure 1. 
205 Differences in treatment between splits
206 At the 200-m split and compared to PP, participants ran faster in CC (mean differences = 
207 0.94 ± 0.29 s, p = 0.009, d = 0.42) and CP (1.21 ± 0.38 s, p = 0.010, d = 0.57). At the 400-m 
208 split, participants ran faster in CC compared to baseline (-0.87 ± 0.25, p = 0.006, d = 0.55), 
209 PC (-0.91 ± 0.28 s, p = 0.009, d = 0.54) and PP (-1.69 ± 0.28 s, p = 0.001, d = 0.84). 
210 Similarly, participants ran faster at 400-m in CP compared to baseline (-0.68 ± 0.27 s, p = 
211 0.031, d = 0.41), PC (-0.72 ± 0.31 s, p = 0.044, d = 0.41) and PP (-1.40 ± 0.28 s, p = 0.001, d 
212 = 0.72). At the 600-m split, participants ran faster in CP compared to baseline (-0.94 ± 0.27 s, 
213 p = 0.005, d = 0.64) and PP (-0.81 ± 0.33 s, p = 0.043, d = 0.47). Participants also ran faster 
214 at 600-m in PC compared to baseline (-1.01 ± 0.31 s, p = 0.008, d = 0.60), CC (-0.61 ± 0.23 s, 
215 p = 0.024, d = 0.36) and PP (-0.88 ± 0.33 s, p = 0.023, d = 0.46). No differences were shown 
216 between any treatments at the 800-m split (p > 0.05), but participants ran faster at 1000-m in 
217 CC compared to baseline (-1.08 ± 0.43 s, p = 0.030, d = 0.52) and PP (-0.98 ± 0.40 s, p = 
218 0.035, d = 0.45). All differences between each treatment and split are shown in figure 2. 
219 Differences in peak heart rate and RPE between treatments
220 Repeated measures ANOVA revealed no differences between treatments for HRpeak (F(4, 40) = 
221 1.198, p = 0.327, η2 = 0.084) and RPE (F(4, 40) = 0.892, p = 0.641, η2 = 0.009). Across all 
222 treatments, mean HRpeak and RPE average scores ranged from 180 to 184 bpm (183.5 ± 2.3 
223 bpm) and 9 to 10 (9.6 ± 0.4), respectively. 
224 Discussion
225 We used a balanced placebo design to investigate the effect of a placebo and caffeine on 
226 pacing strategy during 1000-m running time-trials. Collectively, our results indicate that the 
227 belief of receipt of caffeine improved performance, which was associated with a significant 
228 increase in speed during the first 400-m of the time-trial. In contrast, the hidden and open 
229 administration of caffeine and placebo, respectively, did not improve performance compared 
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230 to baseline. Participants ran faster between 400- and 600-m during the hidden administration 
231 of caffeine, but time to complete the trial overall was similar to baseline. 
232 In our study, the effect of believing to have ingested caffeine improved performance to the 
233 same magnitude as actually receiving caffeine. These findings complement previous findings 
234 in this area, in which participants were able to significantly improve their performance after 
235 being falsely informed they had received caffeine.30,31 However, in addition to previous 
236 studies investigating the placebo effect of caffeine,4,30-32 we also examined participants’ 
237 pacing strategy during the trial, in order to establish if a change in pacing might help explain 
238 the performance improvements. Given that we informed participants that they had received 
239 caffeine in the CC and CP treatments, this information appears to have influenced their belief 
240 of how fast they could perform, influencing the goal-directed process of decision-making 
241 regarding how to distribute the available energy resources.33 Results indicated that 
242 participants were significantly faster at 400-m than baseline and also faster at 200- and 400-m 
243 than when they were given a placebo and informed it was a placebo. This highlights that the 
244 belief of receipt of caffeine, influences the pacing strategy at the start of a 1000-m running 
245 time-trial, impacting on performance. 
246 While both belief and actual receipt of caffeine improved performance at the start of the time-
247 trial, only the actual receipt of caffeine improved performance in the latter stages. At 1000-m, 
248 participants ran significantly faster than baseline during the open administration of caffeine. 
249 This suggests that caffeine may offset fatigue during the final stages of a 1000-m time-trial. It 
250 has been reported that caffeine directly affects neuromuscular output,34 which increases 
251 muscular endurance and subsequently offsets fatigue.35 However, no improvements in 
252 performance at 1000-m were shown during the hidden administration of caffeine. Therefore, 
253 the belief of receipt of caffeine was primarily responsible for the ergogenic effect of caffeine. 
254 These results are similar to Atlas and colleagues, 36 who reported that the benefits of an 
255 opioid drug were augmented after open administration compared to hidden and to a placebo 
256 described as the drug. In the same study, follow up fMRI data revealed that drug and placebo 
257 effects activate different neurobiological pathways, suggesting that the benefits from the drug 
258 and placebo are additive. From the results reported in the present study, it could be suggested 
259 that caffeine and placebo use different neurobiological pathways that affect performance. 
260 Thus, when caffeine is administered openly, the verum and placebo components of caffeine 
261 may combine to provide a greater improvement in performance. However, while these data 
262 show additive effects for caffeine in the latter stages of the trial, it does not exclude the 
263 possibility that other treatments may show interactive effects (i.e. use the same mechanisms). 
264 A paucity of evidence in sport and exercise science is available in this area and future 
265 research needs to design studies that examines the additive or interactive effects of treatments 
266 and placebos. 
267 Table 1 shows large variability between each treatment, which indicates that some 
268 participants may be more likely to respond to a placebo than others. It is recognised that a 
269 participant responding to a placebo can vary from study to study1,2 and even those who do 
270 respond, may not do so consistently.37 Researchers often focus on single-factor casual 
271 mechanisms such as expectation theory4,31 or classical conditioning.38,39 However, placebo 
272 effects are a manifestation of several factors, such as the context in which the treatment is 
273 administered, the person administering it, and the psychology of the athlete (e.g. personality, 
274 beliefs, and intentions). Beedie et al. 37 suggest that variability of the placebo effect can be a 
275 function of 1) an athlete’s response to the verum component of a treatment (e.g. caffeine); 2) 
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276 an athletes response to the placebo component only; and 3) an athletes response to both the 
277 verum and placebo component. To increase knowledge and understanding of the placebo 
278 effect, research is needed that helps identify the mechanisms underlying the variation in 
279 placebo responsiveness. 
280 Similar to previous research,4,31,40 no differences in peak heart rate or perceived exertion was 
281 found between treatments. Given that the aim of a pacing strategy is to ensure physiological 
282 limits are not surpassed while performing at an optimal level,15 a limitation of this study was 
283 that the growth curve of heart rate and perceived exertion during each trial was not measured. 
284 Future research should measure the differences in slopes of heart rate and RPE at each split to 
285 provide a better insight into the variability in intraindividual patterns of change over time 
286 between treatments. 
287
288 Conclusion
289 In conclusion, this is the first study to show that the belief of receipt of caffeine improves 
290 1000-m running time-trial performance on competitive level athletes. That is, believing to 
291 have ingested caffeine, improved performance to the same magnitude as actually receiving 
292 caffeine. These improvements were associated with an increase in speed during the first-part 
293 of the time-trial. While slight changes in pacing strategy were demonstrated during the mid-
294 part of the time-trial with the hidden ingestion of caffeine, overall no changes compared to 
295 baseline were shown. Therefore, for practitioners aiming to maximise the benefits of caffeine 
296 on an athlete’s performance, they should couple the administration of caffeine with a positive 
297 belief of its effectiveness to increase the likelihood of that athlete improving performance.
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397 Figure captions
398 Figure 1. Mean split time between each treatment. Note: Data are means ± 95% CI. * = p < 
399 0.01 vs. CC and CP. ** = p < 0.01 vs. CC and CP
400 Figure 2. Differences in times between treatment and splits. Note: *PP vs. CC and CP (p < 
401 0.05). **CC and CP vs. baseline, PC and PP (p < 0.05). #PC vs. baseline, CC and PP(p < 
402 0.05) and CP vs. baseline and PP (p < 0.05). †CC vs. baseline and PP (p < 0.05)
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403 Tables
Table 1. Mean times (s) to complete 1000-m time-trials in each treatment
Participant Baseline CC CP PC PP
1 166.9 164.3 165.4 172.1 165.1
2 187.3 182.9 180.9 187.1 193.1
3 179.4 174.9 175.4 174.7 178.2
4 176.4 171.1 170.5 173.7 175.3
5 168.4 164.1 160.3 163.0 164.8
6 180.4 178.4 178.7 177.8 184.5
7 169.3 164.6 165.9 165.9 169.8
8 166.3 162.5 163.7 164.3 168.1
9 183.3 180.4 179.2 182.4 181.6
10 175.2 173.3 173.6 173.9 179.1
11 181.8 182.8 184.4 182.4 183.9
Mean ± SEM 175.9 ± 0.55 172.7 ± 0.60 172.6 ± 0.60 174.3 ± 0.59 176.7 ± 0.68
Note: CC = Told caffeine/given caffeine; CP = Told caffeine/given placebo; PC = Told placebo/given caffeine; PP = Told placebo/given 
placebo
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